Navigation Links
Novel medication improves ovarian cancer treatment
Date:10/31/2007

Newport Beach, Calif. October 31, 2007 A new study appearing in International Journal of Gynecological Cancer states that Bevacizumab, a biologic anti-cancer agent that prevents tumor growth by interfering with the formation of new blood vessels, may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer.

Ovarian cancer is the fifth most common cancer in women, accounting for nearly 14,000 deaths annually in the United States. Despite the use of chemotherapy treatment, nearly 70 percent of all ovarian cancer patients will eventually succumb to their disease. Consequently, studies have continued to investigate the activity of novel medications in combination with standard therapy to improve overall and disease-free survival in ovarian cancer patients.

Bevacizumab has been studied clinically and was recently approved as a treatment for metastatic colon cancer and non-small cell lung cancer. Currently, Bevacizumab is also being studied as a treatment to improve patient survival rates for breast and kidney cancers. Since Bevacizumab has a unique mechanism of action and a favorable safety profile, the medication is not associated with unreasonable levels of toxicity. However, previous studies have reported that gastro-intestinal perforations and hypertension may be a consequence of treatment involving Bevacizumab. The results from our research suggest that the combination of Bevacizumab and standard therapy for the treatment of ovarian cancer may be promising, particularly with regard to safety and efficacy, says Dr. Bram Goldstein, co-author of the study.


'/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
Source:Eurekalert

Page: 1

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Gene enchances radiation therapy - A novel approach to fight cancer
3. A novel augmentation
4. Novel biopsy technique for prostate cancer
5. Novel computer model for breast cancer
6. Novel research on liver cancer
7. Novel way to fight cancer
8. Novel test for bowel cancer
9. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
10. Novel Therapy for Chronic Problem
11. Blood Sugar Kept In Control By Novel Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... VEGAS , June 26, 2016 ... to value-based care operating models within the health care ... enable greater financial efficiency , Deloitte offers a ... the key business issues impacting efficient cost optimization: labor ... , These services facilitate better outcomes and better ...
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
Breaking Medicine Technology: